Fumagillin treatment of hepatocellular carcinoma in rats: An in vivo study of antiangiogenesis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

338

HTML

2338

Tables (1-4)

277

Sum=2953

Feb 14, 2005 (publication date) through Nov 27, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Feb 14, 2005; 11(6): 771-777
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.771

Table 2 Body weight of rats at wk 20 and 24.

Weight: median [range]; P value: non-parametric test (Mann-Whitney U test) Group A (control): 372 [350-380] g at wk 20 and 380 [351-394] g at wk 24.

Citation: Sheen IS, Jeng KS, Jeng WJ, Jeng CJ, Wang YC, Gu SL, Tseng SY, Chu CM, Lin CH, Chang KM. Fumagillin treatment of hepatocellular carcinoma in rats: An in vivo study of antiangiogenesis. World J Gastroenterol 2005; 11(6): 771-777
URL: https://www.wjgnet.com/1007-9327/full/v11/i6/771.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i6.771